ACADIA Pharmaceuticals Inc.
ACAD
$25.36
-$0.09-0.35%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 264.57M | 244.32M | 259.60M | 250.40M | 241.96M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 264.57M | 244.32M | 259.60M | 250.40M | 241.96M |
| Cost of Revenue | 98.69M | 98.66M | 122.53M | 85.46M | 94.46M |
| Gross Profit | 165.88M | 145.66M | 137.07M | 164.94M | 147.50M |
| SG&A Expenses | 133.51M | 126.37M | 130.08M | 118.39M | 117.06M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 232.19M | 225.03M | 252.61M | 203.86M | 211.53M |
| Operating Income | 32.37M | 19.29M | 6.99M | 46.54M | 30.44M |
| Income Before Tax | 40.21M | 27.78M | 161.09M | 38.81M | 37.18M |
| Income Tax Expenses | 13.55M | 8.79M | 17.34M | 6.04M | 3.79M |
| Earnings from Continuing Operations | 26.67M | 18.99M | 143.74M | 32.77M | 33.39M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 26.67M | 18.99M | 143.74M | 32.77M | 33.39M |
| EBIT | 32.37M | 19.29M | 6.99M | 46.54M | 30.44M |
| EBITDA | 35.31M | 22.24M | 12.20M | 49.11M | 33.01M |
| EPS Basic | 0.16 | 0.11 | 0.86 | 0.20 | 0.20 |
| Normalized Basic EPS | 0.15 | 0.10 | 0.05 | 0.20 | 0.14 |
| EPS Diluted | 0.16 | 0.11 | 0.86 | 0.20 | 0.20 |
| Normalized Diluted EPS | 0.15 | 0.10 | 0.05 | 0.20 | 0.14 |
| Average Basic Shares Outstanding | 167.83M | 166.81M | 166.54M | 165.97M | 165.55M |
| Average Diluted Shares Outstanding | 168.68M | 167.67M | 166.70M | 166.18M | 166.17M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |